ABT ABT
Company Analysis
Latest News
Abbott CEO Purchases $2 Million in Company Stock After Price Drop
Abbott Laboratories Chairman and CEO Robert B. Ford purchased 18,800 shares of common stock. The transaction totaled approximately $2 million. Ford acquired...
Abbott Laboratories' Valuation and Margin Compression Questioned After Fiscal Year 2025 Results
Abbott Laboratories faces scrutiny over profitability and valuation following its full-year 2025 financial results. Analysis highlighted a compressed net...
Abbott Faces Supply Chain Scrutiny in India Over Codeine-Based Cough Syrup Abuse Investigation
Abbott Laboratories (ABT) is facing new regulatory uncertainty after Indian authorities launched an investigation into its supply chain, Abbott Healthcare,...
đź”´ Abbott is trading 11.4% down today after Q4 revenue miss and weak Q1 guidance
ABT is trading at $106.93, down 11.4%, following disappointing fourth-quarter earnings where revenue missed consensus and Q1 2026 guidance fell short of...
đź”´ Abbott is trading 6% down in pre-market ahead of Q4 earnings call
ABT is trading at $113.76 (-5.77%) in pre-market ahead of its Q4 2025 earnings conference call scheduled for 9:00 AM ET. Consensus expectations are set for...
Abbott Laboratories' Q4 FY25 adjusted EPS grew 12% driven by 10.4% organic growth in Medical Devices.
Abbott Laboratories reported Q4 2025 sales of $11.5 billion, representing organic growth of 3.0% (or 3.8% excluding COVID-19 testing), and adjusted EPS of...
Abbott Receives European Approval for Advanced Atrial Fibrillation Catheter
Abbott received CE Mark approval in Europe for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, on January 20, 2026. The device treats atrial...
FDA Finalizes Class I Recalls for Abbott Glucose Sensors; Lawsuit Filed
The FDA finalized four Class I recalls for Abbott's continuous glucose monitoring (CGM) sensors. This action follows safety concerns Abbott initially reported...
Abbott Laboratories stock little changed as market closed for MLK Day; Tariff concerns weigh on healthcare sector
Abbott Laboratories (ABT) fell 1.43% to close at $121.76 following the announcement of 10% tariffs on eight European nations, creating significant geopolitical...
Abbott's FreeStyle Libre 3 Plus Gains Nationwide Public Funding in Canada
Abbott Laboratories announced that its FreeStyle Libre 3 Plus sensor has secured broad public funding across all Canadian provinces, significantly expanding...
Abbott Laboratories gains momentum on AI diabetes platform and analyst upgrades ahead of Q4 earnings
Abbott Laboratories (ABT) received positive analyst sentiment, including a price target increase to $169 from Barclays, following the showcase of its new...
Abbott Launches AI-Powered Libre Assist Feature for Diabetes Management at CES 2026
Abbott launched Libre Assist, a new feature integrated into its Libre mobile app. The tool is designed to help people with diabetes understand the potential...
Abbott Laboratories Eyes 2026 with Strategic Focus on Biowearables and Metabolic Health
Abbott Laboratories enters 2026 strategically focused on metabolic health and consumer-facing biowearables, exemplified by its Lingo platform and planned...
Abbott Laboratories Boosts Dividend 7% and Sees Legal Alert Withdrawn for Exact Sciences Acquisition
Abbott Laboratories delivered positive news, notably announcing a 7% dividend increase, raising its quarterly payout to $0.63. This move, highlighted earlier...
Abbott Faces Product Safety Crisis Amid New Device Approval
Abbott Laboratories faces a critical product safety issue following an FDA report on December 23, 2025, linking its Freestyle Libre Plus Continuous Glucose...
Abbott Secures FDA Approval for Volt PFA System to Treat Atrial Fibrillation
On December 22, Abbott Laboratories received FDA approval for its Volt™ Pulsed Field Ablation (PFA) System, designed to treat atrial fibrillation (AFib). This...